Immunotherapy

Targeting the Untargetable: New Antibody Disrupts Key Protein in Aggressive Breast Cancer

Researchers at MUSC Hollings Cancer Center have developed an antibody targeting the SFRP2 protein, opening a new front in the battle against triple-negative breast cancer.

Read more

UCSD Study Decodes Enzymatic Role in Cancer Genome Instability, Paving Way for AI-Driven Therapies

Researchers at UC San Diego utilize artificial intelligence to map how specific enzymes drive tumor evolution, offering new hope for predicting drug resistance and personalizing cancer treatment.

Read more

Breakthrough Antibody Targeting SFRP2 Protein Halts Aggressive Breast Cancer in Preclinical Models

Researchers at MUSC Hollings Cancer Center have developed a humanized antibody that neutralizes a key protein driving tumor growth and metastasis in triple-negative breast cancer.

Read more